Investors

Download Investor Presentation
Company Overview
Most Recent Shareholder Letter
Email Alerts
Stay informed and receive company updates straight to your inbox
Recent News
AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that its CEO John Huemoeller has been...
AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their publication in collaboration with researchers at Arizona State...
AXIM Launches New Eye Care Website; Establishes Platform for Commercialization
AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, today announced the launch of its new mobile-optimized website designed to provide doctors, researchers...

Latest Annual Filing
Fiscal Year Ended Dec 31, 2020
Investor Contact Information
Company
AXIM Biotechnologies, Inc.
6191 Cornerstone Court, E., Suite 114, San Diego, CA 92121
T: +1 858 923-4422
Investor Relations
T:
investors@aximbiotech.com
Transfer Agent
Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088
info@actionstocktransfer.com
www.actionstocktransfer.com